...
机译:DNA损伤反应和修复(DDR)基因突变对非小细胞肺癌PD-(L)1免疫检查点抑制的疗效的影响
Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School;
Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School;
Medical Oncology Dana-Farber Cancer Institute;
Cancer Program;
Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School;
Lowe Center for Thoracic Oncology Dana-Farber Cancer Institute Harvard Medical School;
Medical Oncology Dana-Farber Cancer Institute;
Cancer Program;
Department of Informatics Dana-Farber Cancer Institute;
Massachusetts Institute of Technology;
Department of Radiology Brigham and Women's Hospital Harvard Medical School;
Department of Pathology Brigham and Women's Hospital Harvard Medical School;
Center for DNA Damage and Repair (CDDR) Dana-Farber Cancer Institute;
机译:DNA损伤反应和修复(DDR)基因突变对非小细胞肺癌PD-(L)1免疫检查点抑制的疗效的影响
机译:246?根据不同PD-L1表达亚组的临床病理学和肿瘤突变负荷及其对非小细胞肺癌中PD-(L)抑制效果的影响
机译:通过协同抑制DNA损伤反应和免疫检查点途径来提供对小细胞肺癌的刺痛
机译:下一代测序对非小细胞肺癌抗蛋白酶激酶抑制剂进行下一代测序检测的低负荷EGFR突变的预测疗效
机译:K-ras和p53突变和DNA修复基因多态性作为肺癌的生物标记。
机译:使用靶向下一代测序表征小细胞肺癌中的肿瘤突变负担和免疫检查点抑制的功效
机译:DNA损伤修复基因突变表明用免疫检查点抑制剂治疗的结肠直肠癌的良好预后